



IAP10 Rec'd PCT/PTO 18 NOV 2005

PCT

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on November 16, 2005.

INFORMATION DISCLOSURE
STATEMENT
Patent Application
Docket No. BB-149
Serial No. 10/539,827

David Saliwanchik

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : *not yet assigned*
Art Unit : *not yet assigned*
Applicants : Thomas Schwarz, Agatha Schwarz : .
Serial No. : 10/539,827
Filed : June 20, 2005
Conf. No. : *not yet assigned*
For : Uses of Interleukin-18 for Treating Skin Disorders Associated with UV Radiations

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:


The above-referenced patent application was filed in the U.S. Patent Office as a national application under 35 USC §371. Copies of the International Search Report and copies of the references cited therein were made available in the national stage file; however, for the Examiner's convenience, the applicants are enclosing herewith copies of the cited references as well as a copy of the International Search Report.

Attached is a PTO/SB/08 form which lists the references attached.

In accordance with 37 CFR §1.56, the applicants hereby request that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

DRS/hey

Attachments: Form PTO/SB/08; copies of cited references.



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/539,827
Filing Date	June 20, 2005
First Named Inventor	Thomas Schwarz
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	BB-149

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/BH/	R1	KISHIDA, T. et al. "In Vivo Electroporation-mediated Transfer of Interleukin-12 and Interleukin-18 Genes Induces Significant Antitumor Effects Against Melanoma in Mice." <i>Gene Therapy</i> , 2001, p. 1234-1240, Vol.8, No.16.	
/BH/	R2	NAGAI, H. et al. "Gene Transfer of Secreted-Type Modified IL-18 Gene to B16F10 Melanoma Cells Suppresses In Vivo Tumor Growth through Inhibition of Tumor Vessel Formation." <i>Journal of Investigative Dermatology</i> , 2002, p. 541-548, Vol. 119, No. 3.	
/BH/	R3	KANG JAE SEUNG et al. "Enhanced IL-18 Production by UV-B Irradiation Requires ROI and AP-1 Signaling in Human Keratinocyte Cell Line HACAT." <i>Biochemical and Biophysical Research Communications</i> 2002, p. 289-295, Vol. 298.	
/BH/	R4	SCHWARZ, A. et al. "Interleukin-12 Suppresses Ultraviolet Radiation-induced Apoptosis by Inducing DNA Repair." <i>Nature Cell Biology</i> , 2002, p. 26-31, Vol. 4.	
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature	/Bruce Hissong/	Date Considered	06/07/2008
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.